XML 30 R12.htm IDEA: XBRL DOCUMENT v3.19.1
Inventories
 12 Months Ended
Dec. 31, 2018
Inventory Disclosure [Abstract]  
Inventories Inventories
The Company's net inventories consisted of the following as of December 31:
20182017
Raw materials and work in process$18,378,450 $3,156,002 
Consigned inventory937,006 249,964 
Finished goods, net of reserve8,511,887 3,331,882 
Total inventories27,827,343 6,737,848 
less non-current inventories(15,749,000)— 
Total inventories classified as current$12,078,343 $6,737,848 
The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value. At December 31, 2018 and 2017, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.3 million and $0.2 million, respectively.
In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total at December 31, 2018 and 2017. Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment. As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories that are classified as non-current and included in the raw materials and work in process inventory at December 31, 2018. Non-current inventories also include $0.8 million in Vibativ finished goods.